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ABSTRACT 
Relevant developments have been achieved in the last twenty years in the search for 
opioid agonists and antagonists with selectivity for each receptor subpopulation. Recently, 
new benzomorphan derivatives have been synthesized and compounds with substituted 
cyclopropylmethyl functionalities at N-l position showed high affinity and selectivity for 
K opioid receptor subpopulations. MPCB and CCB were selected as specific K agonists. 
The affinity ofCCB was two-fold the USO,488H one. Mixed peptide-heterocyclic compounds 
have been derived from these compounds and important informations on binding processes 
of K ligands have been obtained. 
Key words: Opioid Agonists and Antagonists. Selective Ligands. Bivalent Ligands. 
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RESUMEN 
En los últimos veinte años se ha llevado a cabo una intensa investigación sobre la 
búsqueda de agonistas y antagonistas selectivos de cada subtipo de receptores opiáceos. 
Recientemente, se han sintetizado nuevos derivados benzomorfánicos y compuestos con 
restos ciclopropilmetílicos sobre N-l que muestran alta afinidad y selectividad por los 
receptores K . Los compuestos MPCB y CCB se han seleccionado como agonistas espe-
cíficos K. La afinidad de CCB es dos veces mayor que la del compuesto USO,488H. De 
estos compuestos se han derivado interesantes compuestos con estructura de peptido-
heterocido y se han obtenido importantes informaciones sobre los procesos de binding a 
los receptores K. 
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INTRODUCTION 
One of the key problem in Medicinal Chemistry is selectivity. Selective 
molecules can be used as pharmacological tools to investigate the mechanism of 
action and the physiological role of endogenous ligands and might possess 
reduced side effects when used as drugs. Nevertheless, in many cases the design 
of se1ective compounds is complicated by the existence of multiple receptor 
subpopulations. 
Focusing our attemption on opioid ligands, as there are at least three opioid 
receptors (named J.L, K and 8) (1), the search in the last two decades has been 
totaHy devoted to the design and the synthesis of selective agonists and antagonists 
for each type of receptor. Although several different approaches have been used 
by scientists to develop selective compounds, aH recognize to morphine congeners 
an important role of peptidomimetics, as they mimic suitable relative conformations 
of essential functional groups present in the structure ofthe N-terminal fragment 
of endogenous ligands. 
lnitial studies in the field started with the e1egant work of Portoghese and 
Takemori (2), which at the end of the seventies developped a very selective and 
long lasting antagonist for J.L receptor subpopulation: [3-FNA (3), an alkylating 
agent derived from [3-naltrexamine capable of preventing the binding of morphine 




Extending this approach, Rice et al. synthesized several J.L, K and 8 affinity 
labels using isothiocyanate, bromoacetamido or methylfumaramido groups as 
alkylating functions on fentanyl, etonitazene or endo-ethenotetrahydrooripavine 
skeletons (4). A different approach was later used to develop K selective antagonists: 
the so called Bivalent Ligand Approach (5, 6). The synthesis and SAR studies 
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of dimeric naltrexamines joined via the C-6 carbon atom through a connecting 
unit led to the hypothesis that selectivity can be achieved using suitable spacers 
able to prevent the binding on vicinal recognition sites of particular opioid 
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the monomers is probably due to favourable binding interactions of the second 
monomer with a second opioid receptor or with a proximal non-opioid binding 
site (7). In certain cases, evidence was achieved that these compounds bridge 
vicinal opioid receptors. In fact, the dimeric ligand with both (-)-pharmacophores 
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exhibited a considerable higher potency enhancement than the dimeric compound 
obtained j oining an opioid active (-)-enantiomer with an inactive (+ )-enantiomer 
when compared with the monovalent monomeric (- )-antagonist (8, 9). 
These results, supporting the hypothesis that vicinal receptors are the recognition 
sites involved in the bridging of the bivalent ligand, led to the development of 
nor-BNI (10, 11), a very selective kappa opioid antagonist with a Ilhe selectivity 
ratio of 25 (naltrexone 0.2). Dimerization of 11 or 8 peptidic ligands has also 
been attempted, and informations regarding the active conformations of endogenous 
ligands when bind different receptor subpopulations have been obtained (see, 





(Tyr -D-Ala-Phe-Gly-Tyr-Pro-Ser-NH -CH2-)2 
Recently, important non peptidic ligands have been obtained following the 
Message-Address hypothesis (16), which attempted to rationalize the ligand-
receptor recognition processes. The hypothesis starts from the observation that, 
despite a cornmon N-terminal tetrapeptide fragment, endogenous opioid peptides 
activate different receptor subpopulations. It has been suggested that the cornmon 
sequence contains a "Message" capable of activating the transductional process 
of the receptor complexo On the contrary, the different C-terminal fragments 
confer different receptor selectivity by containing in suitable conformations 
additional functional groups specific for the interaction with certain opioid 
receptor subpopulations. In this model the conformation of the Phe4 residue 
seems to playa key role in inducing selectivity, while the Gly2-Gly3 aminoacidic 
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CH2 - MT 
10, e-PMTC 11, ~-PMTC 12, b-PMTC 
MT = (-)-normetazocine 
chain might play the role of a spacer as it permit to both Message and Address 
fragments to assume particular suitable relative conformations. An important 
consequence of such a hypothesis is that morphinelike pharmacophores, as 
being capable of mimicking the Tyrl residue of endogenous ligands should be 
able to support suitable moieties which might modulate opioid receptor selectivity. 
In fact, it has been found experimental evidences which clearly shows that 
morphine derived pharmacophores can be converted in b-selective ligands simply 
connecting in C-6 a b-address, i.e., Phe-Leu-OMe, which is present in Leu-Enk, 
by means of a suitable spanner chain. Analogously, the same pharmacophore 
H 
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afforded selective K-ligands by connecting in C-6 a K-address such as Phe-Leu-Arg-
Arg-lle-OMe, wbich is present in Dyn-A, a K selective endogenous ligand (17). 
The design of selective opioid ligands based on this hypothesis has been 
used by several groups. Portoghese and coworkers (18) obtained o-selective 
antagonists, thus confirming the key role of the phenyl ring conformation in 
driving the selectivity toward certain receptor subpopulations. Sorne naltrexone 
derivatives, such as NTI, resulted very potent and selective o-antagonists. 
Conforrnational analysis in solution and in the solid state, together with 
experiments of molecular dynamics, evidentiated a possible conformation of a 
pharmacophore required for binding with delta sites. AIso 0-1 and 0-2 selective 
molecules carne from these studies. 
Much more difficult was the application of this hypothesis to the design of 
selective agonists. However, as several recent papers established that with the 
activation of K opioid receptors it might be possible to elicit analgesia without 
sorne of the undesired opioid effects of morphine (19-21), several scientists 
have been deeply involved in the search of kappa selective componds. 
On1y few years ago sorne compounds structurally unrelated to morphine 
showed significative K selectivity, i.e. , U50,488H (22), PD117302 (23) and 
BRL52537 A (24). 
el el 
el 
It has been suggested that a key role for selectivity was played by the 
relative distance and the particular relative conformation of the functional groups 
mirnicking the functionalities present in Tyr' and Phe4 residues. To betler 
explore tbis hypothesis, my research group designed and synthesized a series of 
phenyl carboxyesters derived from N-(cyclopropylmethyl)nor-metazocine (25). 
The rationale for tbis approach was based on sorne simple assumptions: (i) 
conformational analysis of K selective ligands suggest that the optimal distance 
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between the basic nitrogen and the phenolic ring is 6-8 Á; (ii) SAR analysis on 
U50,488H analogs put in evidence stringent relative conforrnational requirements 
for the phenyl ring which mimics the Phe4 residue by respect to the basic 
nitrogen functionality; (iii) a hydrogen-bonding functionality seems to be importani 
for binding with an accessory recognition site close to that for the aromatic ringo 
The choice of (-)norrnetazocine as a pharrnacophore has been made on tho 
assumption that several benzomorphan derivatives although possessing 11 preference 
are also 1C agonist. It was then possible that norrnetazocine, although a suitable 
pharmacophore for both fl and 1C receptors may be switched to 1C selectivity onl, 
adding suitable substituents supporting a phenyl ring and an H-bonding functionali~ 
with optimal distance and relative conforrnation by respect to the phenolic rinJ 
and the basic nitro gen. Molecular modelling studies on potential target compounds 
induced us to select the cyclopropylrnethyl group as a spacer. The carboxyestet! 
group was introduced to probe for an accessory site on the receptor capable o( 
interacting with an H-bonding functionality and to have inforrnations on tho. 
stereospecificity of the ligand-receptor interaction. Among the synthesiz 
compounds, MPCB resulted a specific 1C agonist with an affinity for K receptors 
1/12 times lower than U50488H (25). It was possible to hypothesize a similatl 
approach to K receptors for both benzomorphan derivatives and arylacetamidea 
and perhaps the same receptor site. On the basis of these results, the optimization 
process of the lead brought us to synthesize CCB (26), a 4'-chloro analog of 
MPCB, which resulted still specific for 1C receptors but with a nanomolar 
affmity. We hypothesize that the contemporary presence of a subsituted phenyI 
ring and the carboxyester functionality on the same carbon atom of the cyclopropy 
methyl substituent is essential for 1C specificity and for high affmity in th' 
senes. 
Although CCB binds to 1C receptors with higher affmity, MPCB does it in 
a stereospecific manner, thus suggesting that the molecule rnight assume a 
conforrnation which rnirnics that assumed by the N-terminal tetrapeptide fragment 
of Dynorphins in the binding with the receptor. Linking peptide fragments, to 
the carboxylic functionality of MPCB, we observed improved binding affmity 
probably due to a better interaction of ligands with membrane peptides. As 
specificity is still mantained, we can thus hypothesize that the C-terminal 
fragment of Dynorphin is essential not for binding, but for helping the tetrapeptide 
fragment in assurning the right conforrnation for the binding with kappa receptors 
subpopulations (27). 
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